Dental Care Clinics in Hockessin, DE Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 Raymond L Para.dds, Pa Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 720 Yorklyn Rd, Ste 120, Hockessin, DE 19707 Phone: 302-234-2728 Fax: 302-234-3326 |
William E Gonce Dds Pa Dentist Medicare: Not Enrolled in Medicare Practice Location: 1127 Valley Rd Ste 207, Hockessin, DE 19707 Phone: 302-235-2400 Fax: 302-235-2404 |
Dentistry Of Hockessin Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1127 Valley Rd Ste 203, Hockessin, DE 19707 Phone: 302-235-2400 |
Matthews Dental Associates, Pa Dentist Medicare: Not Enrolled in Medicare Practice Location: 451 Hockessin Cors, Hockessin, DE 19707 Phone: 302-234-2440 |
Dental Management Strategies Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 500 Lantana Dr, Hockessin, DE 19707 Phone: 302-239-5917 Fax: 302-239-3657 |
News Archive
CSL Biotherapies initiates clinical trials of Influenza A/H1N1 2009 vaccine in the US
CSL Biotherapies has announced the initiation of the company's first U.S. clinical trials of its candidate Influenza A/H1N1 2009 vaccine. Study investigators will administer vaccinations to the first U.S. study volunteers today, August 24. The studies will determine the safety of CSL's candidate vaccine and its ability to elicit an immune response (also referred to as immunogenicity) in adults and children.
Patients can reduce frequency of Botox- Cosmetic injections and still receive same benefits: Research
Patients can decrease the frequency of Botox- Cosmetic injections after approximately two years and still receive most of the same wrinkle-smoothing cosmetic benefits, according to new research at Oregon Health & Science University.
Clementia expands enrollment to include children with FOP in ongoing Phase 2 clinical trial
Clementia Pharmaceuticals, Inc. today announced the initiation of enrollment of children as young as 6 years old in the company's ongoing Phase 2 study of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP).
Isis, Genzyme submit European MAA for mipomersen to treat familial hypercholesterolemia
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. today announced that Genzyme has submitted a marketing authorization application (MAA) to the European Medicines Agency seeking approval for the 200 mg weekly dose of mipomersen for the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
› Verified 4 days ago